Background: Breast cancer is the second most common cancer overall (1.4 million cases, 10.9%)and ranks 5th as cause of death (458,000. 6.1%).The present study was aimed to find the pattern of expression of ER, PR, HER-2/neu and to correlate ER, PR status with respect to various clinicopathlogical factors like HER-2/neu over expression, histological grade, tumor size, lymphnode metastasis, lymphovascular invasion and age of the patient. Materials and Methods: Data from 139 patients was collected and correlation of ER, PR status with various clinicopathological factors was analysed. Results: Mean age at diagnosis was 48.5 years, 56.8% cases being ≤50years of age. Tumor size ranged from 1 to 12 cm. Most lesions (57.5%)were>2 to 5 cm in size. The predominant morphology was Infiltrating Duct carcinoma-NOS (90.6%). Majority of cases presented as grade II(46.7%)lesions and lymph node involvement was seen in 66.9%. 49.6% cases were ER+, 49.6% cases were PR+, and HER-2/neu was positive (3+)in 15.8% cases. Older patients were mostly ER+PR+. Low grade tumors were mostly ER+PR+ as compared to high grade tumors. HER-2/neu status revealed an inverse association with hormone receptor positivity. No correlation was found between hormone receptor positivity and lymph node metastasis. Lymphovascular involvement was noted more in hormone negative ER-PR-tumors. Conclusion: ER and PR expression in our patients was found to be comparable to the studies done in Indian subcontinent, but lower than studies done in west, but triple negative breast cancer prevalence was relatively higher in our study (34.5%).
INTRODUCTION
It is estimated that 12.7 million new cancer cases and 7.6 million cancer deaths occurred in 2008 world wide. Lung cancer remained the most common cancer in the world both in terms of cases (1.6 million cases, 12.7% of total)and deaths (1.4 million deaths and 18.2%). Breast cancer is the second most common cancer overall (1.4million cases, 10.9%) but ranks 5th as the cause of death (458,000, 6.1%). Cancers of the Lung, stomach and liver predominate among males in developing regions (42% of new cancer cases, 48% of the total cancer deaths), while as breast and cervical cancers represent 33% of the new cancer cases in females, but only 25% of the corresponding cancer deaths. Incidence rate varies from 19.3 per 100,000 women in Eastern Africa to 89.9 per 100,000 women in Western Europe, and is high (greater than 80/100,000) in developed regions of the world (except Japan) and low (less than 40/100,000)in most of the developing regions. The range of mortality rates is less (approximately 6-19/100,000)because of the more favorable survival of breast cancer in (high incidence) developed regions. As a result, breast cancer ranks as 5th cause of death from cancer overall (458,000 deaths), but it is still the most frequent cause of cancer death in women in both developing (269,000 deaths, 12.7% of total) and developed regions. 1 India is a subcontinent with wide ethnic, cultural, religious and economic diversity. With rising incidence and awareness breast cancer is the commonest cancer in urban Indian females and the second commonest in the rural Indian women. As per the ICMR-PBCR data, breast cancer is the commonest cancer among women in urban registries of Delhi, Mumbai, Ahmadabad, Calcutta, and Trivandrum where it constitutes >30% of all cancers in females. In the rural PBCR of Barshi, breast cancer is the second commonest cancer in women after cancer of the uterine cervix. 2 Breast cancer is a biologically heterogeneous disease and patients with the same diagnostic and clinical prognostic profiles can have markedly different clinical outcomes. 3 Breast cancer survival is linked to early detection, timely appropriate treatment and genetic predisposition. Prognosis and management of breast cancer are influenced by many clinical, pathologic and molecular features which include, histopathologic type, grade of tumor, size of tumor, lymph node metastasis, Estrogen receptor ER status, Progesterone receptor PR status and C -erbB-2 (HER-2) status of the tumor. 4, 5 In the present times determination of hormone status on biopsy specimen is advocated as standard practice.
Estrogen is an important mitogen exerting its activity by binding to its receptor(ER)and found in 50 -80% of breast cancers. 5 Endocrine treatments are assigned to antagonize the effects of estrogen. The presence of hormone receptors (ER & PR) in the tumor tissue correlates well with the response to hormone therapy and chemotherapy. 6 Progesterone receptor PR is expressed in 60 -70 % invasive breast carcinomas with a higher positivity in older age and post menopausal women. Loss of PR by tumor cells is associated with a worse prognosis. 5, 7 Patients with large tumors, poorly differentiated morphology, increased number of axillary lymph node metastasis and higher stage tumors have more chances of an ER & PR negative status. 5, 8 Expression of ER and/or PR generally is associated with a better outcome. Survival and response to hormone therapy are most favorable among women with tumors positive for both ER and PR, intermediate for tumors discordant on receptor status and least favorable for tumors negative for both. 4 HER-2/neu also known as C-erbB-2 is a proto-oncogene located on chromosome 17. It is amplified and the protein (HER -2) over expressed in 15-25% of invasive breast carcinomas with associated poor prognosis. Over expression of HER-2/neu is a good predictor of response to transtuzumab (herceptin), but not a positive predictor of response to chemotherapy or overall survival. 5 Studies have shown that in contrast to the western literature, percentage of estrogen and progesterone receptor (ER and PR) positive tumors in Indian subcontinent is persistently low. 9 The present study was undertaken to observe the trend and to analyze the status of hormone receptor expression in breast cancer at our institution and to assess their value in terms of established prognostic markers like size of tumor, grade of tumor, lymphovascular infiltraton, HER-2/neu status, and lymph node metastasis.
MATERIALS AND METHODS
A total of 139 patients were enrolled for the present study. The study was approved by the hospital ethics committee. All the operated cases of cancer breast who were referred/ visited our department from January 2009 to December 2012 for adjuvant treatment were enrolled in the study. Patients were registered in the Department of radiation oncology and a radiotherapy file for each patient was maintained. Informed consent was taken from all patients. The relevant information including, details about pre-surgical investigations, surgical details, investigations of metastatic work up, post operative complete histopathological details like type, modified Bloom Richardson grade, lymph node involvement, lymphovascular status, Estrogen receptors ER, Progesterone receptors PR status, HER-2/neu and other relevant investigations were noted in the proforma.
Patients with histopathology showing benign tumors, incomplete histopathological details, incomplete surgical details and those patients in whom no/incomplete information about ER, PR, and HER-2/neu status was available were excluded from the present study. Data of all patients was compiled and assessed for: -The pattern of expression of ER/PR {ER+, PR+, ER-, PR-} and HER-2/neu in invasive breast cancer in patients visiting our institution.
-Correlation of ER, PR status with respect to HER2/ neu over expression, modified Bloom Richardson grade of tumor, size of tumor, lymph node metastasis, lymphovascular invasion and age was done.
The Estrogen receptor ER and Progesterone receptor PR were interpreted on immunohistochemistry as positive when at least 1% of the tumor cells showed positive nuclear staining. HER-2/neu score of 3+ was taken as positive by immunohostochemistry method. For equivocal results (2+), ISH (in situ hybridization) tests were advised.
RESULTS
After proper scrutiny, a total of 139 cases were included in the present study. Table 1 shows the age distribution of patients. Mean age at presentation was 48.5 years. The youngest patient was 23 years old and the oldest patient was 75 years of age at the time of diagnosis. Majority of the cases 79 (56.8%) were ≤50 years of age. One hundred thirty six (97.8%) cases presented in female breast whereas only 3 (2.1%) cases were found in male breast.
In our study 97.84% cases were married where as 2.1% cases who presented to our hospital for adjuvant treatment were unmarried. Left breast was more commonly involved i.e. 75 (53.9%) whereas right breast was involved in 64 (46%)cases. Quadrant involvement in left breast was: Upper outer 52%, upper inner 14.6%, lower outer 14.6%, lower inner 8%, central 8% and 2.6% cases had more than one quadrant involvement in left breast where as quadrant involvement in right breast was: Upper outer 46.8%, upper inner 15.6%, lower outer 18.7%, lower inner 4.6%, central 9.3%, and 4.6% cases had more than one quadrant involvement in right side.
Modified radical mastectomy was done in 104 (74.8%) patients, 28 (20.1%)cases had undergone conservative surgeries (lumpectomy with axillary clearance in 16 (57.1%) cases, wide local excision with axillary clearance in 8 (28.5%) cases, quadrantectomy with axillary clearance in 4 (14.2%) cases) whereas 7 (5%) cases had undergone modified radical mastectomy with reconstruction of breast as well. Infiltrating ductal carcinoma (IDC)was the predominant morphological category with IDC NOS (Not otherwise specified) in 126 (90.6%) cases. Four cases (2.8%) had Infiltrating Lobular carcinoma, 2 (1.4%) cases had invasive mucinous carcinoma, 2 (1.4%) cases had IDC with mucinous features and 1 (0.7%) case each of Invasive apocrine carcinoma, solid variant of papillary carcinoma, medullary carcinoma breast, invasive duct carcinoma with lobular pattern and neuroendocrine features, mixed special tubular cibriform and infiltrating duct carcinoma were seen.
Mean number of lymph nodes dissected out were 10.9, highest being 50. Mean number of lymph nodes having metastasis were 4.0 lymph nodes. Ninety three (66.9%) cases had axillary lymph node metastasis, where as in 46 (33%) cases no lymph nodes were involved. 1-3 lymph nodes were involved in 50 (35.97%) cases, 4-9 nodes in 25 (17.9%) cases and more than 9 nodes were involved in 18 (12.9%) cases.
Mean size of tumor was 3.30 cm ranging from 1 to 12 cm. 80 (57.5%) patients had a tumor size of greater than 2 cm to 5 cm, 40 (28.7%) cases had a tumor size of ≤2cm. Only 9 (13.6%) cases had a tumor size of >5 cm. In our study 13 (9.3%) cases had modified Scarff-Bloom-Richardson Grade Ι, 65 (46.7%) cases had Grade ΙΙ and 61 (43.8%) cases had Grade ΙΙΙ tumors on histopathology.
Hormone receptor status was divided into four groups (ER+PR+), (ER+PR-), (ER-PR+), and (ER-PR-), Figure 1 shows the hormone receptor expression. 69 (49.6%) cases were ER positive, 70 (50.3%) cases were ER negative, where as 69 (49.6%) cases were PR positive and 70 (50.3%)cases were PR negative. Out of 139 patients in our study 22 (15.8%)cases were HER -2/neu positive (3+) whereas 117 (84.1%)cases were negative. 8 (5.7%) cases were ER+, PR+, HER-2/Neu positive (3+), whereas 48 (34.5%) cases were triple negative i.e. ER-, PR-, HER-2/neu -ve. 51 (36.6%) cases were ER+, PR+, HER-2/ neu-and 12 (8.6%) cases were ER-, PR-, HER-2/neu +.
Among the triple negative breast cancer patients majority 23 (47.9%) had grade ll tumors followed by 22 (45.8%) cases with grade lll tumors. Only 3 (6.2%) cases had grade l tumors. Among the triple negative breast cancer cases, infiltrating ductal carcinoma IDC (not otherwise specified) was the predominant histopathology type seen among 20 (90.9%) cases with grade lll tumors, 22 (95.6%) cases with grade ll tumors and in all 3(100%) cases with grade l tumors. 1(4.3%) case with grade ll triple negative breast cancer had infiltrating ductal carcinoma with mucinous features. Among triple negative breast cancer cases with grade lll tumors, 1(4.5%) patient had histopathology of infiltrating lobular carcinoma whereas 1 (4.5%) patient had infiltrating ductal carcinoma with lobular pattern and neuroendocrine features.
Lymphovascular invasion on histopathological examination was noted in 49 (35.2%) cases only, of which 18 (36.7%) Expression of ER and/or PR generally is associated with a better outcome. 4 Adjuvant hormonal therapy should be given to women whose breast tumor contains hormone receptor proteins regardless of age, menopausal status, involvement of axillary lymph nodes or tumor size. 9 The prevalence of hormone receptor positive breast cancer in Asian countries has been found to be lower than in western world where more than 50% tumors express hormone receptors, however number of studies performed on this topic is much less in Asian communities as compared to the western world. 9 In western studies ER is expressed in 70-90% of invasive lobular carcinoma and in 70-80% of invasive ductal carcinoma, and PR is expressed in 60 -70% of invasive breast carcinomas. [14] [15] [16] Sastre-Garaux et al 15 found a positive expression of estrogen receptors more frequently in infiltrating lobular carcinoma ILC (79%)and in mixed infiltrating lobular and infiltrating duct carcinoma ILC/IDC (83%) than in non lobular infiltrative carcinomas NLIC (72%). For progesterone receptors a positive expression was found in 63% of infiltrative lobular carcinoma ILC and of NLIC non lobular infiltrative carcinomas and in 69% of ILC/IDC (NOS). Zafrani et al 16 found ER to be expressed in 81% of cases by immunohistochemistry in a prospective series of 793 infiltrating breast cancer patients. Christopher L Li et al 17 found that from 1992 to 1998 the overall proportion of breast cancers that were ER+ and PR+ increased from 75.4% to 77.5% and from 65.0% to 67.7% respectively. These increases were limited to women of 40 to 69 years of age.
In our study 69 (49.6%) cases were ER+, 70 (50.3%) cases were ER-, 69 (49.6%) cases were PR+ and 70 (50.3%) cases were PR-. 59 (42.4%) cases were both ER+PR+, whereas 60 (43.1%) cases ER-PR-, 10 (7.1%) cases were ER-PR+, and ER+PR-respectively ( Figure 1 12 Patil et al, 24 S Krishnamurthy et al 22 reported 25.8%, 19.9%, and 18.5% cases as triple negative breast cancers in their respective studies. Triple negative breast cancer is an aggressive phenotype affecting younger age group and has poor prognosis. Now a day's immunohistochemistry, microassay techniques, and cytogenetics are necessary for exact diagnosis, better prognostication and for application of newer modalities of treatment in breast cancer patients. 22 By adding CK 5/6 and EGFR as the positive markers to the triple negative phenotype, a significantly worse outcome group can be identified among triple negative cases -the basal subtype. The basal phenotypes have more aggressive pathological features than the non-basal phenotypes. 25 
CONCLUSION
In our study majority(56.8%)of patients were less than 50 years of age, older patients were more likely to be ER+PR+ than younger patients. Breast cancer was found in 3 (2.1%)male patients.
HER 2/neu status revealed an inverse association with hormone receptor positivity. Low Grade tumors were mostly ER+PR+ as compared to Grade ΙΙΙ tumors. Size of tumor correlated inversely with the hormone positivity. Small sized lesions were mostly ER+PR+, than large sized tumors. Lymphovascular involvement was more in hormone negative ER-PR-tumors, however there was no correlation between receptor positivity and lymph nodes with metastasis in our study. In our study ER and PR expression in invasive breast cancer patients was found to be comparable to the studies done in India/Asia, but lower than the studies done in West. Triple negative breast cancer prevalence in the study population was also higher (34.5%)than normally reported in literature. More studies involving large sample size need to be done in this context more so in Asian countries.
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